Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 6Neuroblastoma 2Meningioma 2Medulloblastoma 2Recurrence 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 20Etoposide 19Temozolomide 16Carboplatin 16Filgrastim 15Vincristine 11Cisplatin 11Radiotherapy 10Thiotepa 9Melphalan 8Granulocyte Colony-Stimulating Factor 8etoposide phosphate 7Lomustine 7Peripheral Blood Stem Cell Transplantation 6Radiation 5Methotrexate 5Magnetic Resonance Spectroscopy 5Topotecan 4Mesna 4Gemcitabine 4Busulfan 4sargramostim 3gallium Ga 68 dotatate 3Thalidomide 3Stem Cell Transplantation 3Irinotecan 3Ifosfamide 3Donepezil 3Celecoxib 3Automobiles 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Medulloblastoma × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

University of Iowa

Phase 2 Withdrawn
CNS

Medulloblastoma, Meningioma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡